sorafenib has been researched along with benzofurans in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (benzofurans) | Trials (benzofurans) | Recent Studies (post-2010) (benzofurans) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 13,293 | 451 | 4,970 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cecener, G; Egeli, U; Eryilmaz, IE; Guney Eskiler, G; Tunca, B; Yurdacan, B | 1 |
| El-Khouly, OA; El-Messery, SM; El-Sayed, MA; Henen, MA | 1 |
| Eguchi, Y; Iino, S; Kageyama, R; Morimoto, M; Nakamura, S; Okusaka, T | 1 |
1 trial(s) available for sorafenib and benzofurans
| Article | Year |
|---|---|
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Hepatocellular; East Asian People; Humans; Liver Neoplasms; Naphthoquinones; Sorafenib | 2023 |
2 other study(ies) available for sorafenib and benzofurans
| Article | Year |
|---|---|
Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Benzofurans; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Hep G2 Cells; Humans; Liver Neoplasms; Protein-Tyrosine Kinases; Sorafenib | 2019 |
Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer.
Topics: Antineoplastic Agents; Benzofurans; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2022 |